Anis Hamid
@anis_a_hamid
Followers
706
Following
3K
Media
39
Statuses
423
Genitourinary Medical Oncologist & Researcher @MSKCancerCenter. Prostate cancer, germ cell tumor, biomarker dev.
New York, NY
Joined March 2015
RT @BraunMDPhD: 1/ Recently, our lab has worked with outstanding groups (#TeamScience) to address some key questions in kidney cancer immun….
0
16
0
RT @mishabeltran: Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer @NatureComms . https:….
0
21
0
The most fun image & video creation tool in the world is here. Try it for free in the Grok App.
0
197
1K
RT @EdmondMKwan: On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP s….
0
42
0
RT @DrMHofman: Incredible prognostic power of PSMA PET from the updated PROMISE large international registry (PPP2): 3 and 5-yr survival da….
0
58
0
RT @DrRosenbergMSK: The MSK GU Service recently celebrated the illustrious career of Dr. Dean Bajorin. We will miss his wisdom, insight, hu….
0
16
0
RT @EllisLab_: Latest journey in #prostatecancer cell plasticity. Team effort @ChrisSweens1 @kat_morel @BeatrizGerFalc . Work stems from pr….
0
14
0
RT @jclinicalinvest: The mechanism underlying the progression of castration-resistant prostate cancer!. This month’s cover features work by….
0
16
0
RT @Davicioni: Great pod @gu_onc ! thanks for sharing @ChrisSweens1 @Prof_IanD thanks for doing @ANZUPtrials looking fwd to further….
podcasts.apple.com
Podcast Episode · GU Cast | Urology Podcast · 10/11/2024 · 41m
0
4
0
RT @MTouatMD: 📢 Just published in JCO! What is the optimal chemotherapy for oligodendroglioma patients? Our study using data from the natio….
ascopubs.org
PURPOSEPatients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy...
0
31
0
RT @DrJonLim: Great to finally meet all in person! Here we are: @myESMO Translational Research Faculty, chaired by @TurajlicLab. #ESMO24 🔬🧪….
0
7
0
RT @ChrisSweens1: Attention all postdocs - this is an incredible opportunity with a wonderful mentor to help advance great science and your….
0
3
0
RT @wgibson: TP53: .- Discovered 45 years ago, most cited gene all time.- No therapies.- 500 million people currently living will die of TP….
0
257
0
Capping off a month on staff @MSKCancerCenter GU Onc. Much exciting work to be done and a fantastic, welcoming team all around @DrRosenbergMSK @morr316 @DrDarrenFeldman et al. Thankful to mentors + collaborators along the way @ChrisSweens1 @DanaFarber_GU @Prof_IanD @ANZUPtrials
4
2
56
RT @Prof_IanD: @ANZUPtrials celebrates @MargaretMcJann1 as she "retires" (yeah right I suspect there won't be much putting up of feet), and….
0
6
0
RT @ResearchWyatt: Our latest study with @piet_ost, of whole prostates, lymph nodes, and ctDNA at initial diagnosis in de novo metastatic p….
0
64
0
RT @CalumGabbutt: Does the evolutionary history of a cancer predict outcome? In our pre-print, we introduce a new method to measure a cance….
0
38
0
RT @JessicaHawleyMD: #Tweetorial: .Data from Drake Lab and others shows CSPC is immunologically different and not an ‘immune desert’ like C….
0
35
0
RT @mishabeltran: Nice collaboration with @FKhaniPath @willbfx @ElementoLab @notSoJunkDNA and many others - Evolution of structural rearra….
nature.com
npj Precision Oncology - Evolution of structural rearrangements in prostate cancer intracranial metastases
0
6
0
Kudos @ResearchWyatt what a great reflection on cross-disciplinary (scientist-clinician, clinician-scientist) learning and respect inspiring cancer research #ANZUP23
2
2
16